9/29 news. Their top developed product did not meet the criteria to continue further development based on the data collected during 2 studies. That's when they dropped from 1.48 to below 0.40. I bought back in in the .40s with the idea that they will try not to get downlisted. Which means they will have to get back above 1.00.
News 
Market Data 
Discover 
